Ignite Creation Date:
2024-05-06 @ 2:07 AM
Last Modification Date:
2024-10-26 @ 11:14 AM
Study NCT ID:
NCT01976585
Status:
COMPLETED
Last Update Posted:
2022-09-22
First Post:
2013-10-30
Brief Title:
In Situ Vaccine for Low-Grade Lymphoma Combination of Intratumoral Flt3L and Poly-ICLC With Low-Dose Radiotherapy
Sponsor:
Joshua Brody
Organization:
Icahn School of Medicine at Mount Sinai
Organization Data
Organization:
Icahn School of Medicine at Mount Sinai
Class:
OTHER
Study ID:
GCO 13-1347
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Joshua Brody
Lead Sponsor Class:
OTHER
Responsible Party:
Joshua Brody
Responsible Party Title:
Director Lymphoma Immunotherapy Program
Responsible Party Type:
SPONSOR_INVESTIGATOR
Responsible Party Affiliation:
Icahn School of Medicine at Mount Sinai
Old Name:
None
Old Organization:
None
Collaborators
| Name | Class |
|---|---|
| Celldex Therapeutics | INDUSTRY |